18F-Fluciclovine PET-MRI in High-grade Glioma

Description

The purpose of this study is to see if 18F-fluciclovine (Axumin®) PET imaging is useful and safe in the management of children with High Grade Gliomas. Investigators seek to determine if this imaging will help doctors tell the difference between tumor growth (progression) and other tumor changes that can occur after treatment.

Conditions

Glioma, High Grade Glioma, Glioma, Malignant, Glioma Intracranial, Diffuse Glioma

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to see if 18F-fluciclovine (Axumin®) PET imaging is useful and safe in the management of children with High Grade Gliomas. Investigators seek to determine if this imaging will help doctors tell the difference between tumor growth (progression) and other tumor changes that can occur after treatment.

Evaluation of 18F-Fluciclovine PET-MRI to Differentiate Tumor Progression From Post-treatment Changes in Pediatric High-grade Glioma (HGG)

18F-Fluciclovine PET-MRI in High-grade Glioma

Condition
Glioma
Intervention / Treatment

-

Contacts and Locations

Philadelphia

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, 19104

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * 1. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician.
  • * 2. Pregnant or breastfeeding participants.
  • * 3. Participant who would require sedation or anesthesia for imaging beyond standard of care (SOC).
  • * 4. Participants who weigh less than 8 kg.
  • * 5. Participants who cannot avoid contact with a pregnant woman or infant for at least 12 hours following injection.
  • * 6. Participants with a history of abnormal kidney function or creatinine \>= CTCAE v5.0 grade 2 at time of study registration.
  • 7. Participants with primary tumors of the spinal cord.

Ages Eligible for Study

1 Year to 21 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Children's Hospital of Philadelphia,

Mariam Aboian, MD,PhD, PRINCIPAL_INVESTIGATOR, children's hospital of philadelphia

Study Record Dates

2026-12